More GEN Content From This Contributor

• Feature Articles: Therapeutic Cancer Vaccine Options
• Feature Articles: Embryonic Stem Cells: Not Just From Humans
• Feature Articles: BioSimilars Market Ripe for Expansion
• Feature Articles: Producing Biologics Less Expensively
• Feature Articles: Boosting Use of Microbial Systems in Manufacturing
• Feature Articles: Advancing Cancer Vaccines
• Feature Articles: Funding Issues Stymie Pandemic Preparation
• Feature Articles: Superbugs vs. Superdrugs: Race Goes On
• Feature Articles: Managing Asthma and COPD Treatments
• Feature Articles: Is the U.K. Biotech Industry on the Skids?
• Feature Articles: Spain Invests in Quest for Big Biotech Payoff
• Feature Articles: Investigating and Focusing on Ion Channels as Drug Targets
• Feature Articles: Big Pharma's Interest in Vaccine Products on Rise
• Feature Articles: Adoption of Label-Free Technologies Surges
• Feature Articles: Cell Therapy Building on Momentum
• Feature Articles: Central Eastern Europe Targets Biotech
• Feature Articles: Epigenetic-Derived Therapies on Horizon
• Feature Articles: U.K. Works to Keep Its Edge
• Feature Articles: Discovery Aided by Complex Assays
• Feature Articles: Single-Use Systems Drive Down Costs
• Feature Articles: U.K. Biopharma Bouncing Back
• Columns: Working Toward Better, Cheaper Drug Discovery
• Columns: EMD Millipore Takes European Roadtrip
• Feature Articles: Regen Med Nears the Market
• GEN Exclusives: Open Innovation in the Pharma Industry
• Feature Articles: Where Downstream Operations Are Headed
• GEN Exclusives: Poland Invests in Biotech Infrastructure
• GEN Exclusives: Can the U.K. Maintain Its Biomanufacturing Empire?
• GEN Exclusives: Implementing a Full Quality-by-Design Strategy
• GEN Exclusives: Driving Down the Cost of Stem Cell Manufacturing
• GEN Exclusives: U.K. Continues to Invest in GMP Manufactured Biologics and Advanced Therapies
• GEN Exclusives: Smart Process Development Strategies
• Columns: U.K. Aims at $15B Gene Therapy Industry
• Columns: U.K. Bioindustry Plots Its Post-Brexit Course
• GEN Exclusives: Translating Innovation into Therapies
• GEN Exclusives: Will Cell and Gene Therapies Reach a Tipping Point?
• GEN Exclusives: Screening Innovations and 3D Cell Culture Assay Developments Showcased at ELRIG
• GEN Exclusives: UK Biotechs Present Novel Technologies at BioTrinity 2017
• GEN Exclusives: Why is Adaptive Manufacturing of Biologics Difficult?
• GEN Exclusives: BioTrinity Conference Focuses on NextGen Healthcare
• GEN Exclusives: Gene Therapy for Rare Diseases
• GEN Exclusives: Brexit’s Effect on U.K. Life Sciences